Schonfeld Strategic Advisors LLC Ocugen, Inc. Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.45 - $0.88 $26,235 - $51,304	58,300 New	58,300 $31,000
Q4 2022 Feb 14, 2023	SELL	$1.11 - $1.87 $314,118 - $529,191	-282,990 Reduced 74.12%	98,800 $128,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $600,194 - $1.06 Million	342,968 Added 883.44%	381,790 $679,000
Q2 2022 Aug 15, 2022	BUY	$1.83 - $3.45 $3,700 - $6,975	2,022 Added 5.49%	38,822 $88,000
Q1 2022 May 16, 2022	SELL	$2.34 - $4.72 $15,443 - $31,152	-6,600 Reduced 15.21%	36,800 $121,000
Q4 2021 Feb 14, 2022	SELL	$4.38 - $15.67 $36,792 - $131,628	-8,400 Reduced 16.22%	43,400 $198,000
Q3 2021 Nov 16, 2021	BUY	$6.36 - $8.51 $144,372 - $193,177	22,700 Added 78.01%	51,800 $372,000
Q2 2021 Aug 16, 2021	BUY	$5.52 - $15.68 $160,632 - $456,288	29,100 New	29,100 $234,000

123

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $169M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.